Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
Vaccine|March 12, 2018
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccinesKirsten S Vannice, Annelies Wilder-Smith, Alan D T Barrett, et al.
NPJ Vaccines|December 17, 2019
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohortsRaffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, et al.
Vaccine|September 11, 2019
Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseasesMarcia A Blackman, Mark A Marchionni, John Gilly, et al.
Vaccine|June 17, 2023
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant womenThanyawee Puthanakit, Kulkanya Chokephaibulkit, Surasith Chaithongwongwatthana, et al.
The American Journal of Tropical Medicine and Hygiene|March 14, 2008
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive childrenSriluck Simasathien, Stephen J Thomas, Veerachai Watanaveeradej, et al.
The American Journal of Tropical Medicine and Hygiene|February 4, 2015
An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaquesStefan Fernandez, Stephen J Thomas, Rafael De La Barrera, et al.
Vaccine|December 7, 2023
Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccinesKulkanya Chokephaibulkit, Thanyawee Puthanakit, Surasith Chaithongwongwatthana, et al.
Vaccines|June 25, 2026
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai AdultsKriengkrai Prasert, Sutthichai Nakphook, Jiraphut Kittiwatanachod, et al.
The American Journal of Tropical Medicine and Hygiene|March 30, 2016
Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai ChildrenVeerachai Watanaveeradej, Sriluck Simasathien, Mammen P Mammen, et al.
The American Journal of Tropical Medicine and Hygiene|August 5, 2011
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infantsVeerachai Watanaveeradej, Sriluck Simasathien, Ananda Nisalak, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
Vaccine|March 12, 2018
Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccinesKirsten S Vannice, Annelies Wilder-Smith, Alan D T Barrett, et al.
NPJ Vaccines|December 17, 2019
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohortsRaffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, et al.
Vaccine|September 11, 2019
Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseasesMarcia A Blackman, Mark A Marchionni, John Gilly, et al.
Vaccine|June 17, 2023
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant womenThanyawee Puthanakit, Kulkanya Chokephaibulkit, Surasith Chaithongwongwatthana, et al.
The American Journal of Tropical Medicine and Hygiene|March 14, 2008
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive childrenSriluck Simasathien, Stephen J Thomas, Veerachai Watanaveeradej, et al.
The American Journal of Tropical Medicine and Hygiene|February 4, 2015
An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaquesStefan Fernandez, Stephen J Thomas, Rafael De La Barrera, et al.
Vaccine|December 7, 2023
Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccinesKulkanya Chokephaibulkit, Thanyawee Puthanakit, Surasith Chaithongwongwatthana, et al.
Vaccines|June 25, 2026
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai AdultsKriengkrai Prasert, Sutthichai Nakphook, Jiraphut Kittiwatanachod, et al.
The American Journal of Tropical Medicine and Hygiene|March 30, 2016
Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai ChildrenVeerachai Watanaveeradej, Sriluck Simasathien, Mammen P Mammen, et al.
The American Journal of Tropical Medicine and Hygiene|August 5, 2011
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infantsVeerachai Watanaveeradej, Sriluck Simasathien, Ananda Nisalak, et al.
Pageof 12